By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


KaloBios Pharmaceuticals, Inc. 

260 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-243-3100 Fax: 650-243-3260



Company News
KaloBios (KBIO), Post-Shkreli, Vows 'Maniacal' Focus On R&D And Transparency 8/30/2016 7:07:58 AM
Martin Shkreli Sells Remaining Stake of Bay Area's KaloBios (KBIO) 8/29/2016 7:49:13 AM
KaloBios (KBIO) Announces First Patient Dosed In Phase I Study Of Lenzilumab For The Treatment Of Chronic Myelomonocytic Leukemia 7/25/2016 8:56:08 AM
The People Who Made the Most Cash Off of KaloBios (KBIO)'s Bankruptcy Filing 7/21/2016 6:53:58 AM
KaloBios (KBIO) Enters Deal to Buy Back Former CEO Martin Shkreli's Shares 7/7/2016 5:51:24 AM
KaloBios (KBIO) Emerges from Chapter 11 Bankruptcy, Buys Tropical Disease Drug 7/1/2016 8:06:18 AM
Trio of Execs that Saved Martin Shkreli's Old Company KaloBios (KBIO) Could Get $700,000 Award 6/2/2016 6:55:01 AM
KaloBios (KBIO)' New CEO Distances Himself Even Further from Shkreli With Drug Pricing Promise 4/11/2016 7:00:13 AM
KaloBios (KBIO)'s Loans to Get Out of Bankruptcy Tied to Reducing Martin Shkreli's Stake 3/22/2016 7:16:37 AM
Scorned Biotech KaloBios (KBIO) Taps New CEO in Hopes of Moving Past Martin Shkreli Controversy 3/7/2016 6:34:30 AM